DUBLIN, Ireland, and Boston MA, November 23 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
Share Talk Weekly Stock Market News, Sunday 13th September 2020
We hope you had a great week in the markets and are all staying safe, our newsletter is going out later today so without further ado, let us look back
Amryt Pharma PLC (AMYT.L) POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
AMRYT ANNOUNCES POSITIVE TOP LINE RESULTS FROM PIVOTAL PHASE 3 “EASE” TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
Share Talk Bulletin Board Heroes, Tuesday 11th December 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Amryt Pharma Plc (AIM:AMYT) New distribution agreement signed
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has signed an exclusive distribution agreement for Lojuxta® (lomitapide) covering Romania and Bulgaria with
Shard Capital: Insights into the small pharmaceutical company sector (video)
Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
Amryt Pharma Plc (AIM:AMYT) Senior Management Team Appointment
Amryt Pharma, a biopharmaceutical company focused on treatments for rare and orphan diseases, is pleased to announce the appointment of Patrick Jordan as Vice-President of Global Distributor Markets.
Amryt Pharma Plc (AIM:AMYT) Placing to raise £13.3M
Amryt Pharma Plc, the biopharmaceutical company focused on rare and orphan diseases announces a placing to raise €15.0 million (£13.3 million) through the issuance of 66,477,651 new Ordinary Shares at
Amryt Pharma, Joe Wiley CEO
Share Talk speak to #AMYT CEO Joe Wiley about their recent 'Transformational Licence Agreement' RNS of 5 Dec 2016. We also get some more background information about Amryt Pharma and